4.7 Article

mEAK-7 Forms an Alternative mTOR Complex with DNA-PKcs in Human Cancer

Journal

ISCIENCE
Volume 17, Issue -, Pages 190-+

Publisher

CELL PRESS
DOI: 10.1016/j.isci.2019.06.029

Keywords

-

Funding

  1. Common Fund of the Office of the Director of the National Institutes of Health
  2. NCI
  3. NHGRI
  4. NHLBI
  5. NIDA
  6. NIMH
  7. NINDS
  8. National Institute of Dental and Craniofacial Research [1F30DE026048-01, R01-DE016530, T32-DE007057]
  9. Stuart & Barbara Padnos Research Award from the Comprehensive Cancer Center at the University of Michigan

Ask authors/readers for more resources

MTOR associated protein, eak-7 homolog (mEAK-7), activates mechanistic target of rapamycin (mTOR) signaling in human cells through an alternative mTOR complex to regulate S6K2 and 4E-BP1. However, the role of mEAK-7 in human cancer has not yet been identified. We demonstrate that mEAK-7 and mTOR signaling are strongly elevated in tumor and metastatic lymph nodes of patients with non-small-cell lung carcinoma compared with those of patients with normal lung or lymph tissue. Cancer stem cells, CD44+/CD90+ cells, yield elevated mEAK-7 and activated mTOR signaling. mEAK-7 is required for clonogenic potential and spheroid formation. mEAK-7 associates with DNA-dependent protein kinase catalytic subunit isoform 1 (DNA-PKcs), and this interaction is increased in response to X-ray irradiation to regulate S6K2 signaling. DNA-PKcs pharmacologic inhibition or genetic knockout reduced S6K2, mEAK-7, and mTOR binding with DNA-PKcs, resulting in loss of S6K2 activity and mTOR signaling. Therefore, mEAK-7 forms an alternative mTOR complex with DNA-PKcs to regulate S6K2 in human cancer cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available